NCT06986447
Assessment of Non-Invasive Testing in Major Liver-Related Outcomes
Enrolling by Invitation
Not specifiedAges 18–80ObservationalHRI-MAIL-NIT
~1,689 participants
Updated 2026-03-27 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Occurrence of major adverse liver outcomes (MALO)
Measured over 2 years
Conditions
Where it's being run
8 sites across 3 statesTexas4
Arizona3
Ohio1
Study leadership
- Mazen Noureddin, MD, MHSc · PRINCIPAL_INVESTIGATOR · Houston Research Institute
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Occurrence of major adverse liver outcomes (MALO)2 years
Variceal bleeding, hepatic encephalopathy, ascites, progression from MELD 13 to 15, liver transplant, death attributable to liver disease, progression to large varices